Antiviral Research

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Retrieved on: 
Thursday, January 25, 2024
EMBO Gold Medal, Professional, Heinz, Max Planck Society, CSO, University Medical Center, I&I, Louis-Jeantet Prize for Medicine, UMG, German, Antiviral Research, Psoriasis, WLA, Animal welfare, Creativity, Inflammation, VHH, Pharmaceutical industry

JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.

Key Points: 
  • JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.
  • Görlich serves as a director of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT).
  • According to MPI-NAT, Görlich has received several other scientific awards including the Heinz Maier-Leibnitz Prize, the EMBO Gold Medal, the Alfried Krupp Prize, the WLA Prize 2022, and the Animal Welfare Research Prize of the German Federal Ministry of Food and Agriculture.
  • Amir Reichman, Scinai's CEO, commented, "On behalf of Scinai's team, I offer sincere congratulations to Dirk on being awarded the 2024 Louis-Jeantet Prize.

Acceligen Announces Innovative Scientific Paper on Breeding PRRSV Resistant Pigs

Retrieved on: 
Tuesday, January 16, 2024
Farm, Livestock, Betaarterivirus suid 1, Research, Farmer, Animal, Health, Breeding, Paper, Partnership, University, PRRSV, Tournament selection, Antiviral Research, Fever, Lethargy, Periodic breathing, Appetite, Vomiting, Depression, Champaign–Urbana metropolitan area

EAGAN, Minn., Jan. 16, 2024 /PRNewswire/ -- Acceligen, the leading Precision Breeding company for food animals, today announced publication in Antiviral Research of their groundbreaking work on breeding PRRSV resistant pigs.

Key Points: 
  • A SUBSIDIARY OF RECOMBINETICS INC., ACCELIGEN ANNOUNCES INNOVATIVE SCIENTIFIC PAPER ON BREEDING PRRSV RESISTANT PIGS
    EAGAN, Minn., Jan. 16, 2024 /PRNewswire/ -- Acceligen, the leading Precision Breeding company for food animals, today announced publication in Antiviral Research of their groundbreaking work on breeding PRRSV resistant pigs.
  • Porcine Reproductive and Respiratory Syndrome Virus, also known as PRRSV, is a virus which results in substantial economic harm to pig farms on a global scale.
  • The publication shows that Acceligen is meeting this challenge by uniquely breeding pigs resistant to PRRSV-1 and PRRSV-2.
  • Dr. Tad Sonstegard, co-author and CEO of Acceligen said, "The results of this research demonstrate that Acceligen's approach to breed PRRSV resistant pigs opens an alternative avenue for making this trait available to the entire industry."

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Retrieved on: 
Monday, December 11, 2023
China Biologic Products, VHH, Aerosol, CDMO, Psoriasis, Antiviral Research, University Medical Center, Inflammation, Inhalation, COVID-19, Omicron, Infection, Antiviral drug, SARS-CoV-2, Max Planck Society, I&I, Single-domain antibody, Coronavirus, Arthritis, Weight loss, UMG, Vaccine, Pharmaceutical industry

JERUSALEM, Dec. 11, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, is pleased to announce the publication following peer-review of an article titled "Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters" in the prestigious scientific journal Antiviral Research.

Key Points: 
  • The Antiviral Research paper covers several aspects of the NanoAbs, including their structure, mechanism of action, neutralization of a wide range of SARS-CoV-2 variants including Omicron, production in yeast, and formulation into aerosols.
  • "Our next pipeline project is an anti-IL-17 NanoAb for the treatment of autoimmune diseases such as plaque psoriasis and psoriasis arthritis.
  • Amir Reichman, CEO of Scinai, added "The publication of this prestigious journal article comes at an auspicious time for our company.
  • It is currently undergoing copyediting and typesetting and will soon be updated with the final version at this same link.

OyaGen, Inc. announces a new publication for its COVID therapeutic in development and publication of related patents

Retrieved on: 
Monday, September 18, 2023
Antiviral Research, OyaGen, COVID, Pharmaceutical industry

ROCHESTER, N.Y., Sept. 18, 2023 /PRNewswire/ -- OyaGen, Inc. Today the company announced publication in Antiviral Research of studies evaluating the mechanism of action of its proprietary COVID therapeutic in preclinical development.

Key Points: 

ROCHESTER, N.Y., Sept. 18, 2023 /PRNewswire/ -- OyaGen, Inc. Today the company announced publication in Antiviral Research of studies evaluating the mechanism of action of its proprietary COVID therapeutic in preclinical development.

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, May 4, 2023
Communication, Arm, Therapy, Virology, Coronavirus, COVID-19, NA, Tax, Viral, Roivant Sciences, Research, RNA, CFBV, HBsAg, Tokyo International Conference on African Development, Antiviral Research, Patient, Investment, Immune system, RNA interference, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, HBV, Conference, Food, Safety, Nivolumab, Vaccine, Pharmaceutical industry, Cryptocurrency, Arbutus

Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161

Key Points: 
  • Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161
    WARMINSTER, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reported first quarter 2023 financial results and provided a corporate update.
  • “In the first quarter of 2023, we made meaningful progress advancing our pipeline of HBV and coronavirus assets to address large global market opportunities,” said William Collier, Arbutus’ President and Chief Executive Officer.
  • We expect to announce preliminary data from patients receiving the combination of AB-729, NA therapy and IFN in the second quarter of 2023.
  • Roivant Sciences Ltd. owned approximately 23% of our outstanding common shares as of March 31, 2023.

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, April 12, 2023
Bemnifosbuvir, Truncation, Therapy, Hospital, Virology, Dengue virus, COVID-19, Atea, Pharmacokinetics, Viral, ICAR, QRS, Doctor of Philosophy, QT, QT interval, Plasma, Congress, ECCMID, International Conference on Population and Development, Antiviral Research, Patient, European, Risk, Political moderate, Adolescence, Electrocardiography, Heart rate, Conference, HCV, Infection, Safety, Pharmaceutical industry

These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.

Key Points: 
  • These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.
  • “The MORNINGSKY data also highlight additional potential clinical benefits of bemnifosbuvir.
  • Adverse events leading to treatment discontinuation were observed in 2.8% of patients treated with bemnifosbuvir compared to 7% of patients receiving placebo.
  • Atea will also present clinical data for AT-752, an oral double prodrug of a guanosine nucleotide analog for the treatment of dengue virus, at ECCMID 2023.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 3, 2023
Well, Pancreatic cancer, Society, AIM, Therapy, British Society for Haematology, RNA, COVID-19, Ebola, Erasmus MC, Viral, ICAR, Research, Doctor of Philosophy, AstraZeneca, International Conference on Population and Development, Antiviral Research, Patient, DSM-IV codes, Cancer, Rintatolimod, Immunology, Conference, NYSE, Pharmaceutical industry, Cryptocurrency

OCALA, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today reported its financial results for the fourth quarter and full year 2022 and provided a business update. As previously announced, the Company will host its inaugural conference call and audio webcast, today, Monday, April 3, 2023, at 8:30 AM ET (details below).

Key Points: 
  • Our team is committed to the development of Ampligen for unmet medical needs in cancers, immune disorders and viral diseases.
  • AIM’s goal is to generate near- and long-term value for all stockholders,” commented Thomas K. Equels, Chief Executive Officer of AIM.
  • As of December 31, 2022, AIM reported cash and cash equivalents of $34.2 million, compared to $48.3 million as of December 31, 2021.
  • Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

Retrieved on: 
Thursday, March 16, 2023
Research, Conference, United States Army Medical Research Institute of Infectious Diseases, Mortality, Tropical disease, NYSE, RNA, Viral, Environmental science, Manuscript, University of Cagliari, International Conference on Emerging Infectious Diseases, ICAR, Ebola, Laboratory, AIM, Human, TLR3, PAMP, COVID-19, FDA, Disease, European Medicines Agency, Antiviral Research, EBOV, Doctor of Philosophy, Orphan drug, EVD, Investigational New Drug, Cancer, DSM-IV codes, Therapy, University, Vaccine, Pharmaceutical industry, Central Africa, Rintatolimod

Highlights of the recently published Ampligen data that was presented include:

Key Points: 
  • Highlights of the recently published Ampligen data that was presented include:
    As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection.
  • AIM CEO Thomas K. Equels commented, “In vivo pre-clinical analysis shows that Ampligen has potential as both a prophylactic and an early-onset therapeutic in Ebola virus disease.
  • Animal studies with Ampligen at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories demonstrated 100% protective survival, as compared to 100% mortality in Ebola virus disease.
  • Ultimately, the Company's goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Poster, Conference, Ensitrelvir, Enzyme assay, Viral, Novel, Pan, SARS-CoV-2, Arbutus, International Conference on Emerging Infectious Diseases, Gesellschaft mit beschränkter Haftung, ICAR, Dodi Protero, Virology, Antiviral Research, EC50, Omicron, Therapy, IND, Pharmaceutical industry, Vaccine, Mpro

WARMINSTER, Pa., March 14, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preclinical data for AB-343, our novel oral SARS-CoV-2 Mpro inhibitor, has been presented in poster format at the 36th International Conference on Antiviral Research (ICAR), in Lyon, France.

Key Points: 
  • “We are excited that our preclinical data for AB-343 has been selected for poster presentation at ICAR.
  • Many of the studies compared AB-343 to nirmatrelvir, the active ingredient in Pfizer’s Paxlovid™ and ensitrelvir, the active ingredient in Shionogi’s Xocova®.
  • The results showed that AB-343 targets SARS-CoV-2 Mpro and inhibits viral replication in vitro (EC50 ~ 20nM).
  • Some of these studies were conducted in part with Proteros biostructures GmbH under the discovery research and license agreement entered into in April 2021.

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Conference, Na'aran, Viral, RNA-dependent RNA polymerase, International Conference on Emerging Infectious Diseases, CNRS, ICAR, COVID-19, SLC, Rat, Doctor of Philosophy, CYP450, Urine, HIV disease progression rates, Cirrhosis, ABC, Antiviral Research, CET, SP, Drug resistance, Aix-Marseille University, SARS-CoV-2, Fever Dream, NS5A, BEM, Infection, Sulfur, Plasma, GUK1, Risk, ADME, Methylation, Enzyme, Patient, Metabolism, UGT1A1, Coronavirus, Phosphate, Safety, Discovery and development of NS5A inhibitors, RNA, Hepatitis C, Human coronavirus OC43, Combination, Virus, DENV, Maintenance, Architecture, GalNAc-T activation pathway, Feces, HINT1, Orthornavirae, Dengue virus, RZR, Therapy, NS5, Pharmaceutical industry, Vaccine, Flour, Phosphorus, Bemnifosbuvir, HCV

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of new Phase 1, in vitro and in vivo data that demonstrate key profile attributes of Atea’s lead drug candidate, bemnifosbuvir, for the treatment of COVID-19 and hepatitis C (HCV). Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented. These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.

Key Points: 
  • Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented.
  • These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.
  • These advantages include a higher barrier to resistance and maintenance of antiviral activity in the presence of COVID-19 variants.
  • Additionally, the combination of bemnifosbuvir and ruzasvir for the treatment of HCV demonstrated potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions.